FindTrial
Sign In

FC + rituximab followed by rituximab maintenance treatment in patients with advanced untreated Indolent B-cell Non follicular Lymphomas: phase II study.

FC + rituximab followed by rituximab maintenance treatment in patients with advanced untreated Indolent B-cell Non follicular Lymphomas: phase II study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-002733-39-IT
Enrollment
Unknown
Registered
2007-02-09
Start date
2005-04-06
Completion date
Unknown
Last updated
2012-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previously untreated CD20-positive B-cell advanced indolent non follicular non-Hodgkin Lymphoma (NHL). MedDRA version: 14.1 Level: HLT Classification code 10029621 Term: Non-Hodgkin's lymphomas unspecified histology indolent System Organ Class: 100000004851

Interventions

Trade Name: MABTHERA*EV 2F 10ML 100MG Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentratio

Sponsors

ROCHE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026